AURA Aura Biosciences, Inc.
USHealthcareAs of 2026-07-10 16:00
Why AURA matters now
Aura Biosciences, Inc. (AURA) is a US stock in Healthcare. The latest InvestLog snapshot shows $6.84 with -2.29% on the session and $439.1M in market capitalization; recent performance reads 1-month -14.21% and YTD +16.33%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-33.7M, and EPS of $-0.50. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -22.5%.
The latest indexable market news headline is "Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $17.00; recent insider activity includes Gibney Anthony S filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.99
P/S
0.00
EV/EBITDA
-3.05
DCF Value
$0.67
FCF Yield
-22.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-78.1%
ROA
-81.6%
ROIC
-95.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-33.7M | $-0.50 |
| Q4 2025 | $0.00 | $-25.6M | $-0.40 |
| FY 2025 | $0.00 | $-106.2M | $-1.76 |
| Q3 2025 | $0.00 | $-26.1M | $-0.40 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$17.00
Target (Median)
$17.00
Target Range
$17.00 - $17.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.39
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.